Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus

BioLineRx (BLRX) Appoints New CEO

August 11, 2016 6:47 AM EDT

BioLineRx Ltd. (Nasdaq: BLRX) announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.

Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.

"On behalf of the Board, I would like to thank Kinneret Savitsky for her outstanding leadership and many... More